Cytotoxic Drugs Contract Manufacturing Market | Coherent Market Insights

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• CYTOTOXIC DRUGS CONTRACT MANUFACTURING MARKET
  ANALYSIS
• Cytotoxic Drugs Contract Manufacturing Market, by
  Production Scale (Industrial Scale, Pilot Scale,
  and Laboratory Scale), by Form (Liquid, and
  Solid), by Product Type (Oral and Intravenous),
  and by Region (North America, Latin America,
  Europe, Asia Pacific, Middle East, and Africa) -
  Size, Share, Outlook, and Opportunity Analysis,
  2019 - 2027

3

• Global Cytotoxic Drugs Contract Manufacturing
  Market, by Production Scale (Industrial Scale,
  Pilot Scale, and Laboratory Scale), by Form
  (Liquid, and Solid), by Product Type (Oral and
  Intravenous), and by Region (North America, Latin
  America, Europe, Asia Pacific, Middle East, and
  Africa), was valued at US 6,285.2 million in
  2018, and is expected to exhibit a CAGR of 9.1
  over the forecast period (2019-2027), as
  highlighted in a new report published by .
  Governments in emerging economies such as India
  are focusing on initiatives to increase domestic
  production. For instance, in August 2017,
  according to the Department of Pharmaceuticals
  under the Ministry of Chemicals and Fertilizers
  of government of India proposed 'peak customs
  duty' and suggested setting up of bulk drug parks
  to increase domestic production.

4

• Furthermore, rapid growth in the pharmaceutical
  industry in the Asia Pacific region is expected
  to propel growth of cytotoxic drug contract
  manufacturing market in the Asia Pacific region
  during the forecast period. For instance, in
  September 2019, according to the Indian Brand
  Equity Foundation (IBEF), India pharmaceutical
  industry is expected to reach US 55 Bn by 2020.
  Increasing investment by the market players, in
  order to expand their service and product
  offerings is expected to boost growth of the
  cytotoxic drugs contract manufacturing market
  over the forecast period. For instance, in
  October 2017, Lonza Group established Lonza
  Collaborative Innovation Center (CIC) in new Life
  Science Park in Haifa, Israel. With this, Lonza
  aims to accelerate leading RD projects across
  Lonza's Pharma Biotech segment, and tap into
  potentially transformative biological and
  manufacturing capabilities.

5

• North America is expected to dominate cytotoxic
  drugs contract manufacturing market over the
  forecast period, owing to adoption of growth
  strategies such as product launches, investments,
  facility expansion by the market players in the
  region to expand their market presence. For
  instance, in 2016, Cambrex, a leading small
  molecule API contract manufacturer expanded its
  facility at Iowa, Charles City-based
  manufacturing site, adding 1,000- and 4,000
  gallon glass-lined reactors in 7,500-square-foot
  plant. Moreover, market players are focused on
  collaboration and acquisition strategies to
  expand their market presence and enhance facility
  in the region, which is expected to drive growth
  of the market over the forecast period. For
  instance, in November 2017, CordenPharma
  International, a contract provider of both
  small-molecule APIs and drug products acquired a
  Hospira Boulder facility from Pfizer Inc., a
  54,000-square-foot API manufacturing facility
  located in Colorado, U.S. to build its
  capabilities in high-potency manufacturing.
  According to the expansion strategy, the new
  facility specializes in development, scale-up,
  optimization, and production of highly potent and
  cytotoxic/cytostatic APIs from development to
  commercialization stage.

6
Key Takeaways of the Cytotoxic Drugs Contract
Manufacturing Market

• The global cytotoxic drugs contract manufacturing
  market is expected to exhibit a CAGR of 1 over
  the forecast period, owing to increasing adoption
  of collaboration and acquisition strategies by
  key players and rising trend of contact
  manufacturing. Contract development and
  manufacturing organizations (CDMOs) play a vital
  role in expediting development of innovative
  small molecule drug candidates, as these
  important development activities are often
  achieved through outsourcing partnerships with
  CDMOs
• Among form, liquid segment held dominant position
  in the cytotoxic drugs contract manufacturing
  market in 2018, owing to adoption of expansion
  strategies by the market players. For instance,
  in April 2018, STA Pharmaceutical, a subsidiary
  of WuXi AppTec, signed an investment agreement
  with the Government of Shanghai, to build a new
  research development (RD) center for APIs and
  intermediates located next to the companys
  existing Jinshan drug-substance manufacturing
  site.

7

• Among product type, intravenous segment held
  dominant position in the cytotoxic drugs contract
  manufacturing market in 2018, owing to companies
  focusing on expansion of their manufacturing
  facilities for production of sterile injectable
  and API, in order to increase client base and
  cater to their demand. For instance, in March
  2017, Piramal Pharma Solutions expanded
  manufacturing capabilities in Lexington, U.S. The
  new facility includes installation of a new
  high-speed vial filling line, expansion of the
  state-of-the art laboratories, and associated
  utility support.
• Companies operating in the global cytotoxic drugs
  contract manufacturing market include Lonza
  Group, Piramal Group, Evonik Industries AG,
  Novasep Holding SAS, Merck KGaA (SAFC Pharma),
  Baxter Biopharma Solutions, AbbVie Contract
  Manufacturing, Cambrex Corporation, BSP
  Pharmaceuticals S.p.A., CordenPharma
  International, Catalent, Inc., Albany Molecular
  Research Inc., Evotec, WuXi AppTec Co., Ltd.,
  Pierre Fabre Laboratories, and Dishman Group

8

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  market-insight/cytotoxic-drugs-contract-manufactur
  ing-market-3175

9
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

10
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

11
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/